Heplisav B is a vaccine for preventing hepatitis B virus infection in adults. It is also likely to prevent infection with the hepatitis D virus as this virus is only present in people with hepatitis B infection. Heplisav B is used in accordance with official recommendations. It contains a protein from the hepatitis B virus.
Therapeutic Indication
### Therapeutic indication Heplisav B is indicated for the active immunisation against hepatitis B virus infection (HBV) caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The use of Heplisav B should be in accordance with official recommendations. It can be expected that hepatitis D will also be prevented by immunisation with Heplisav B as hepatitis D (caused by the delta agent) does not occur in the absence of hepatitis B infection.
Therapeutic Area (MeSH)
N/AATC Code
J07BC01
ATC Item
hepatitis B, purified antigen
Pharmacotherapeutic Group
Vaccines
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| hepatitis B surface antigen | N/A | 乙型肝炎病毒表面抗原 |
EMA Name
Heplisav B
Medicine Name
Heplisav B
Aliases
N/ANo risk management plan link.
